A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial

Narelle S. Cox¹*, Beverley Eldridge², Sarah Rawlings³, Julianna Dreger⁴, Jennifer Corda⁵, Jennifer Hauser⁶, Brenda M. Button⁷, Jennifer Bishop⁸, Amanda Nichols⁹, Anna Middleton¹⁰, Nathan Ward¹¹, Tiffany Dwyer¹², Owen W. Tomlinson¹³, Sarah Denford¹³, Alan R. Barker¹³, Craig A. Williams¹³, Michael Kingsley¹⁴, Paul O’Halloran¹⁵, Anne E. Holland¹⁶ and On behalf of Youth Activity Unlimited – A Strategic Research Centre of the UK Cystic Fibrosis Trust

Abstract

Background: Regular participation in physical activity by people with cystic fibrosis (CF) promotes positive clinical and health outcomes including reduced rate of decline in lung function, fewer hospitalizations and greater wellbeing. However adherence to exercise and activity programs is low, in part due to the substantial daily therapy burden for young people with CF. Strict infection control requirements limit the role of group exercise programs that are commonly used in other clinical groups. Investigation of methods to promote physical activity in this group has been limited. The Active Online Physical Activity in Cystic fibrosis Trial (ActionPACT) is an assessor-blinded, multi-centre, randomized controlled trial designed to compare the efficacy of a novel web-based program (ActivOnline) compared to usual care in promoting physical activity participation in adolescents and young adults with CF.

Methods: Adolescents and young adults with CF will be recruited on discharge from hospital for a respiratory exacerbation. Participants randomized to the intervention group will have access to a web-based physical activity platform for the 12-week intervention period. ActivOnline allows users to track their physical activity, set goals, and self-monitor progress. All participants in both groups will be provided with standardised information regarding general physical activity recommendations for adolescents and young adults.

Outcomes will be assessed by a blinded assessor at baseline, after completion of the intervention, and at 3-months followup. Healthcare utilization will be assessed at 12 months from intervention completion. The primary outcome is change in moderate-to-vigorous physical activity participation measured objectively by accelerometry. Secondary outcomes include aerobic fitness, health-related quality of life, anxiety and depression and sleep quality.

Discussion: This trial will establish whether a web-based application can improve physical activity participation more effectively than usual care in the period following hospitalization for a respiratory exacerbation. The web-based application under investigation can be made readily and widely available to all individuals with CF, to support physical activity and exercise participation at a time and location of the user’s choosing, regardless of microbiological status.

Trial registration: Clinical trial registered on July 13, 2017 with the Australian and New Zealand Clinical Trials Register at (ACTRN12617001009303).

Keywords: Physical fitness, Exercise, Telerehabilitation, Goal setting, Application, Online
Background
Cystic Fibrosis (CF) is a complex, multi-system inherited disorder. This progressive disorder is commonly characterised by chronic suppurative lung disease, including bronchiectasis, progressing to respiratory failure [1]. People with CF require repeated admission to hospital to treat respiratory complications; have poor quality of life and life expectancy; experience reduced aerobic fitness and physical functioning, and increased prevalence of anxiety and depression [2]. Higher levels of physical activity participation and aerobic fitness have been associated with improved health outcomes, in particular a slower decline in lung function [3], reduced need for hospitalization [4], and improved prognosis [5] in both children and adults with CF.

Regular participation in moderate-to-vigorous intensity physical activity (MVPA) has numerous health benefits including improved aerobic fitness and bone density, and reduced risk of depression [6]. Regular exercise and physical activity are recommended in CF treatment guidelines [2], to improve aerobic fitness; relieve breathlessness; and positively influence bone accretion, blood glucose control and clearance of pulmonary secretions [7, 8]. Despite the benefits of regular physical activity participation, people with CF demonstrate poor uptake and adherence to programs designed to augment physical activity and exercise [9]. This problem is compounded by the limited range of methods trialled to date to increase physical activity participation by people with CF [10].

Few strategies have been applied in the promotion of physical activity to people with CF. A Cochrane Review of strategies to promote physical activity participation by people with CF identified several studies which employed various forms of exercise training to improve physical activity, in mostly young people with mild CF lung disease [3, 10–13]. No study in the review investigated the effect of strategies such as motivational interviewing or the use of technology or telemedicine in promoting physical activity participation by people with CF. There is limited evidence that interventions of medium-longer term duration, with a requirement for self-directed participation, may be more effective than short-term, supervised training in improving physical activity participation [10].

Technology and telemedicine applications have the potential to create new ways to promote and support physical activity and exercise participation in this population, and are feasible and acceptable to people with CF [14, 15]. Importantly, no physical activity intervention study in people with CF to date has focussed on the period immediately post hospitalization. Objectively measured physical activity levels in adolescents and young adults with CF have been found to decline by over 50% in the first one month following hospital discharge [4]. In other populations with chronic respiratory disease, particularly people with chronic obstructive pulmonary disease (COPD), failure to recover physical activity levels in the month following hospital discharge is associated with an increased likelihood of hospital readmission [16]. Whether a web-based intervention to promote physical activity can effectively improve activity participation, and delay time to next admission, in young people with CF is unknown.

This paper describes the protocol for a randomized controlled trial testing a web-based application to promote physical activity in adolescents and young adults with CF. The aims of the trial are to: 1) investigate the effect of a web-based application (ActivOnline) to promote physical activity participation in young people with CF; 2) assess the effect of a technology based intervention (ActivOnline), in the period immediately following hospital discharge on aerobic fitness, lung function, quality of life, anxiety and depression, sleep quality, and healthcare utilisation in young people with CF. We hypothesise that the web-based intervention will improve uptake and participation in physical activity by young people with CF following a hospital admission for a respiratory exacerbation compared to usual care; that increased physical activity participation will lead to improvements in exercise capacity, lung function, quality of life, anxiety and depression, and sleep quality; and that healthcare utilization will be reduced in the intervention group over 12 months.

Methods
Design
A randomized, controlled, assessor-blinded trial will be conducted at eight Australian sites (Alfred Health, Monash Health and Royal Children’s Hospital, Victoria; Royal Hobart Hospital, Tasmania; Royal Prince Alfred Hospital, Westmead Hospital and Children’s Hospital at Westmead, New South Wales; Royal Adelaide Hospital, South Australia). The Human Research Ethics Committee at Alfred Health approved the study for all sites, and local governance approvals were obtained from all participating sites. The trial was registered at www.anzctr.org.au (ACTRN12617001009303) on July 13, 2017. This trial protocol employs our established methods with respect to randomization procedures, data integrity and management, trial safety monitoring and managing participant withdrawals [17].

Participants and recruitment
Potential participants will be all individuals with CF admitted to hospital for a respiratory cause at the participating sites. To be eligible for inclusion participants will: 1) have a confirmed diagnosis of CF; 2) be aged 12–35 years (inclusive); and 3) have access to the internet via a computer or mobile device. Potential participants will be excluded if they: 1) have a severe co-morbidity limiting mobilisation or physical activity participation (e.g.
orthopedic, cardiac or neurological condition); 2) have been the recipient of a lung transplant; 3) are pregnant; or 4) they (or their parents) are unable to provide informed consent.

Randomisation
Participants will be randomly allocated (1:1) to ‘usual care’ or the ‘ActivOnline’ intervention. A computer-generated, block randomization scheme will be used with stratification for 1) site of recruitment – to allow for differences in local treatment practices including those related to usual prescription of exercise, and 2) whether or not the participant is enrolled in fulltime schooling (primary or secondary versus not in fulltime schooling) as the time of transition from secondary school to university or the workforce is a known time for decline in physical activity participation [18].

Sequence generation will be performed by an individual who is independent of the research team and randomization will occur using an online database. The randomization sequence will be concealed from investigators. Participants will be allocated to groups after completion of one week of physical activity monitoring immediately following discharge from hospital. Participants will not be blind to the intervention, however all outcomes will be measured by an independent assessor blind to group allocation. The flow of participants through the study will be reported according to the recommendations of the Consolidated Standard of Reporting Trials (CONSORT) [19].

Interventions
Usual care
Physical activity and exercise is routinely advised for all patients with CF [20, 21]. All participants will be provided with age-appropriate information regarding recommended guidelines for physical activity participation. Participants will be referred to a free online resource (http://www.nhs.uk/Livewell/fitness/Pages/physical-activity-guidelines-for-young-people.aspx) containing guidelines and information regarding amount and intensity of daily physical activity participation [6]. Physical activities which involve the use of large muscle groups continuously will be encouraged [3], as will the preferred activities of the participants [11].

ActivOnline intervention
Participants randomized to the active intervention group will be given individualized access to the ActivOnline program (www.activonline.com.au) and encouraged to use this for the 12-week intervention period, to track their physical activity, set goals, and self-monitor progress. This will be in addition to usual care.

ActivOnline uses principles of motivational interviewing and cognitive behavioural strategies, with the aim of increasing opportunity and motivation for physical activity participation. It provides a secure portal for recording and reviewing physical activity and exercise participation details. ActivOnline is a mobile platform accessible from any internet browser across a variety of devices including tablets and smartphones. When logging into ActivOnline participants will be prompted to set weekly exercise and physical activity goals, as well as to record details of their physical activity or exercise sessions including total time and step count. To support recording of daily step count participants may use their own activity tracker (e.g. Fitbit) or mobile telephone. A pedometer (Yamax digiwalker SW500, Yamasa Tokei Keiki Co., Ltd., Tokyo, Japan) will be provided to participants on request. Data entered into ActivOnline are displayed in numerical and graphical form to allow visualization of progress over time (see Fig. 1). Participants can choose the frequency of use of ActivOnline, as data can be entered retrospectively. If no activity has been logged for three days, a standardized alert message will be issued by the ActivOnline program and emailed to the participant. Participants in the intervention group will also be able to communicate with research clinicians directly via the messaging system contained within ActivOnline about the trial or their clinical status, should they require. The number and nature of contacts via the messaging system will be recorded.

Outcome measures
Demographic details of age, gender, body mass index (BMI) and lung function will be collected at baseline, prior to hospital discharge. Details pertaining to CF genotype, age at diagnosis and status for pancreatic insufficiency will be obtained from the medical record. Frequency of access to the ActivOnline program and number of exercise sessions recorded will be extracted from ActivOnline.

Participants will undertake assessment of clinical outcome measures at baseline, end intervention and after 3 months follow-up (Fig. 2). The following measures will be recorded:

Primary outcome
The primary outcome will be time spent in moderate-vigorous physical activity (MVPA) as measured objectively using accelerometry. The intensity of physical activity will be monitored using a wrist-worn accelerometer provided to participants for seven days (Actigraph Link; Actigraph LLC, Pensacola, FL 32502 USA). This triaxial accelerometer is validated for the assessment of free-living activity and is a recommended device for the objective assessment of physical activity in individuals with CF [22]. The a priori definition for activity monitoring data to be included in the final analysis is a minimum of three days [23], for ≥10 h of valid wear time in each day.
Average time (minutes) per day spent in MVPA will be reported.

Accelerometers will be initialized (sampling rate 100 Hz) and downloaded using the ActiLife software (v6.10.4; ActiGraph, Pensacola, Fl, USA). Wear-time will be established using ActiLife parameters such that a period of at least 90 min of consecutive activity counts of zero, with a spike threshold of two minutes and 100 counts per minute, will define non-wear time [24]. Pre-specified cut-points will be used to determine time spent in at least moderate intensity activity, with activity intensity thresholds determined by participant age [25, 26].

Secondary outcomes

- Self-reported physical activity participation will also be assessed using the Habitual Activity Estimation Scale (HAES), a validated subjective measure of physical activity participation in young people with CF [27]. Two measures of physical activity participation will allow for comparison between patient perception of activity intensity and objectively measured data.
- Aerobic fitness will be assessed using the Modified Shuttle Test (25 level version; MST-25) [28], an extension of a field test of aerobic capacity which is a reliable and valid measure of exercise capacity in adults and children with CF [29–31]. The MST-25 is a symptom-limited estimated assessment of peak aerobic capacity with distance covered the outcome of interest. It requires participants to walk, or run as necessary, around two markers over a 10-m course in time with a pre-recorded audio signal. Each level of the test lasts for one minute, with the speed

![Fig. 1 ActivOnline. a. ActivOnline website homepage; b-d. ActivOnline data entry portal – data entry screen (b); real time graphical display of data (c); goal setting (d). The image depicted in (a) is legally sourced royalty free stock photo from Adobe Stock](image-url)
increasing by 0.61 km/hr each minute. Participants cease the test when they feel they are no longer able to continue or when they fail to meet the course marker on two consecutive shuttles [29].

- Assessment of the reasons underlying participants decision to engage, or not engage, in physical exercise will be undertaken using the Behavioural Regulation in Exercise Questionnaire (BREQ-2) [32]. The BREQ-2 has been used in young people [33] and adults [34] with a variety of chronic medical and psychological conditions.

- Spirometry measures of forced expiratory volume in one second (FEV$_1$) and forced vital capacity (FVC) will be reported. Spirometry measures will be conducted according to American Thoracic Society/European Respiratory Society (ATS/ERS) standard procedures [35].

- Health-related quality of life (HRQoL) will be assessed using the revised edition of the Cystic Fibrosis Questionnaire (CFQ-R) [36]. The CFQ-R is a valid and reliable tool that provides a disease-specific measure of HRQoL [36].

- Anxiety and depression will be evaluated using the Hospital Anxiety and Depression Scale (HADS) [37] and the Center for Epidemiologic Studies - Depression (CES-D) scale [38]. These scales have been used in establishing the prevalence of anxiety and depression in young people and adults with CF [39].

- As exercise can positively impact both sleep and health outcomes, participants will complete the Pittsburgh Sleep Quality Index (PSQI) [40] self-report measure of sleep quality. The PSQI has been validated widely, and previously used in children and young adults with CF [41].

- Healthcare utilization will be documented from the medical record. Time to next hospital admission and the number of hospital days up to 12 months following completion of the intervention period will be reported.

**Analysis**

**Sample size**

To detect a difference of 20-min per day in MVPA participation between ActivOnline and control groups following the intervention period, a total of 56 participants will be required. This sample size was based on physical activity participation measured post hospitalisation in our population of young adults with CF [4] and assumes a standard deviation of 26 [4] with a power of 80% and a significance level of $p < 0.05$. It was planned to randomize a total of 75 participants to allow for 25% attrition. Over the first 18 months of recruitment there was higher than anticipated attrition for the primary outcome. It was decided to extend recruitment beyond the initial target of 75 to account for this attrition. The original trial registration incorrectly stated a different number of participants (incorrect total 150). This was
due to an error in interpreting the sample size calculation. The correct number of participants required (total for both groups combined) is $n = 56$, with $n = 19$ to allow for 25% attrition, giving a correct total sample size of $n = 75$. In our original registration we had incorrectly assumed that $n = 56$ were required in each group.

**Analysis**
Continuous variables will be analysed by fitting linear mixed models, controlling for recruitment centre and baseline values as required. The proportion of participants who achieve age recommended physical activity will be compared between groups using a chi-squared test. Time to hospital admission will be evaluated using Kaplan-Meier curves and Cox proportional hazards modeling. All data will be analysed by intention-to-treat. Alpha will be set at 0.05.

**Data integrity and management**
Data will be stored on a purpose-built online database (www.adeptrs.com), with encryption, password-protection and restricted access. No identifying information will be stored in the online database.

**Withdrawal**
A participant will be considered to have withdrawn from the study when consent is revoked. If this occurs, no further assessments will be performed. Participants will be informed that data collected up to the time of withdrawal will form part of the study results unless permission is expressly declined. Withdrawn participants will not be replaced. Protocol violations will not constitute grounds for withdrawal. Study withdrawal will not have any impact on care provided by any of the participating sites.

**Monitoring**
The trial will be monitored by an independent Data Safety Monitoring Board (DSMB) comprising a respiratory physician and two clinical research physiotherapists, with consultation with a statistician as required. The DSMB will review data relating to the primary outcome (MVPA participation), as well as quality of life and safety. Data will be presented to the DSMB in a blinded fashion. The DSMB will initially review data at a time six months from the commencement of recruitment, and six months thereafter. Any serious adverse events will be notified immediately to the overseeing ethics committee (Alfred Health) and the relevant site governance committee, as well as to the DSMB. If there are concerns about the safety of participants, the DSMB will make a recommendation to the trial steering committee about continuing, stopping, or modifying the trial.

**Discussion**
Regular physical activity is a key recommended component of international care guidelines for individuals with CF [20, 21], yet only limited methods for supporting patients to adhere to this component of their therapeutic regimen have been investigated. This study will compare the effects of a web-based platform which enables activity tracking, self-monitoring and goal setting, compared to usual care on clinical outcomes and healthcare utilization in adolescents and young adults with CF. Internationally, annual medical expenditure on individuals with CF is 22 times greater than those without CF [42]. Physical activity participation is a low-cost treatment strategy that has the potential to reduce the impact and progression of chronic lung disease in CF, and associated healthcare expenditure. To date, few strategies outside of exercise training programs have been explored as means to promote daily physical activity participation by people with CF [10]. The physical activity promotion strategy under investigation addresses key therapy delivery issues associated with treatment timing and infection control. By providing opportunity for goal-setting and self-monitoring, at a time and place convenient to the patient, challenges of adherence to exercise programs and maintenance of activity following hospitalisation might be reduced.

**Trial status**
Recruitment commenced in September 2017 and remains ongoing.

**Abbreviations**
BREQ2: behavioural regulation in exercise- questionnaire (version 2); CES-D: center for epidemiologic studies -depression scale; CF: cystic fibrosis; CFQR: cystic fibrosis questionnaire – revised; DSMB: data safety monitoring board; FEV₁: forced expiratory volume in one second; HADS: hospital anxiety and depression scale; HAES: habitual activity estimation scale; HRQoL: health related quality of life; MST-25: modified shuttle test (25 level); MVPA: moderate-vigorous physical activity; PSQI: Pittsburgh sleep quality index.

**Acknowledgements**
Members of Youth Activity Unlimited a Strategic Research Centre of the UK Cystic Fibrosis Trust are: Professor Craig Williams (PI), Dr. Alan Barker, Dr. Sarah Denford, Dr. Owen Tomlinson (University of Exeter, UK); Professor Eleanor Main, Dr. Sarah Rand, Ms. Helen Douglas (University College London, UK); Dr. Mandy Byron (Great Ormond Street Hospital for Children, UK); Professor Anne Holland, Dr. Narelle Cox, Dr. Bev Eldridge, Dr. Paul O’Halloran (La Trobe University, Australia); Dr. Kelly Mackintosh, Dr. Melita McNarry, Ms. Mayara Silveira (Swansea University, UK); Dr. Jane Schneiderman, Dr. Greg Wells, Ms. Jessica Caterini (Hospital for Sick Children, Canada). Additional site support from: Dr. Ruth Dentice (RPAH, Sydney, NSW), Ms. Raynuka Lazarus (Westmead Hospital, Sydney, NSW), Dr. Fiona Moran and Ms. Esta Tannebaum (Royal Children’s Hospital, Melbourne), Ms. Belinda Kerr (Monash Health).

* Details of members of Youth Activity Unlimited are listed in the acknowledgements section and can be found online at: http://sshs.exeter.ac.uk/youthactivityunlimited/

**Authors’ contributions**
NSC and AEH conceived the study. NSC, AEH and BE produced the first draft of this manuscript. Study funding was procured by NSC, AEH, POY and CAW together with investigators of Youth Activity Unlimited – a Strategic Research Centre of the UK Cystic Fibrosis Trust. NSC, AEH, BE, BB, SD, ARB, CAW, MK and
POH provided input on the study design. All authors (NSC, AEH, BE, JD, SR, BB AN, JC, JH, JB, AM, NW, TD, OT, SD, ARB, CASH, MK and POH) contributed to the production of the final manuscript. All authors (NSC, AEH, BE, JD, SR, AN, JC, JH, BB, JB, AM, NW, TD, OT, SD, ARB, CASH, MK, POH) will contribute to participant recruitment, intervention delivery, data collection or analysis, and will provide input on data presentation and manuscript preparation. All authors read and approved the final version of this manuscript.

Funding
This study is funded by a Strategic Research Centre grant of the UK Cystic Fibrosis Trust. The UK CF Trust will not interfere with the independence of the authors in regard to the conduct of the trial and will not delay or prevent publication of the study.

Availability of data and materials
Not applicable. Details relating to planned data availability are available in the clinical trials registration at www.anzctr.org.au.

Ethics approval and consent to participate
Ethical approval for this study was granted by the Alfred Health Human Research Ethics Committee (HREC/16/Alfred/188; Project 7/17) in February 2017 providing ethical approval for all study sites under the Single Ethical Review Process (SERP). Local governance approvals were received from each of the participating sites (Monash Health SSA/17/Mon/H/163 RES-17-0000-2140; Royal Children’s Hospital Melbourne SSA/17/RCH/MB/37033A; Tasmanian Health HO/16/799; Children’s Hospital at Westmead SSA/18/SCHN/419; Westmead Hospital SSA/18/WMEAD/482; Royal Prince Alfred Hospital SSA/19/RPAH/84; Royal Adelaide Hospital SSA/19/CALH/176 11109). Written informed consent/assent will be obtained for all participants, with written informed consent obtained from a parent or guardian for participants under 16 years old.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1. Monash University, La Trobe University and Institute for Breathing and Sleep, Level 6, The Alfred Centre, 99 Commercial Road, Melbourne, Vic 3004, Australia.
2. La Trobe University, Level 4, The Alfred Centre, 99 Commercial Road, Melbourne, Vic 3004, Australia.
3. Monash Children’s Hospital Monash University and La Trobe University., 246 Clayton Rd, Clayton, Vic 3168, Australia.
4. Monash University, La Trobe University and Alfred Health, Level 6, The Alfred Centre, 99 Commercial Road, Melbourne Vic 3004, Australia.
5. Physiotherapy Department Royal Children’s Hospital, 50 Flemington Road Parkville, Victoria 3052, Australia.
6. Tasmanian Adult Cystic Fibrosis Unit, Royal Hobart Hospital, OPG Box 1061, Hobart, Tasmania 7000, Australia.
7. Departments of Physiotherapy and Respiratory Medicine Alfred Health and Department of Medicine, Nursing and Health Sciences, Monash University, 55 Commercial Road, Melbourne, Vic 3004, Australia.
8. Adult Cystic Fibrosis Service, Westmead Hospital, PO Box 533, Wentworthville, NSW 2145, Australia.
9. Monash Children’s Hospital/Monash Health CF Service, 246 Clayton Rd, Clayton, Victoria 3168, Australia.
10. Physiotherapy Department, Children’s Hospital at Westmead, Hawkesbury Road, Westmead, NSW 2145, Australia.
11. Physiotherapy and Cystic Fibrosis Services, BB05506, Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, Australia.
12. Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney, PO Box 170, Lidcombe, NSW 1825, Australia.
13. Children’s Health & Exercise Research Centre (CHERC), Sport and Health Sciences, College of Life and Environmental Sciences, St. Luke’s Campus, University of Exeter, Heavitree Road, Exeter, Devon EX1 2LU, UK.
14. La Trobe Rural Health School, La Trobe University, Bendigo, Vic 3552, Australia.
15. School of Psychology and Public Health, La Trobe University, Bendigo, Vic 3552, Australia.
16. Monash University La Trobe University, Alfred Health and Institute for Breathing and Sleep, Level 6, The Alfred Centre, 99 Commercial Road, Melbourne, Vic 3004, Australia.

Received: 28 July 2019 Accepted: 20 September 2019

Published online: 19 December 2019

References
1. Koch C, Holby N. Pathogenesis of cystic fibrosis. Lancet. 1993;341:1065–9.
2. Yankaskas J, Marshall B, Sufian B, Simon R, Rodman D. Cystic fibrosis adult care. Consensus conference report. Chest. 2004;125(Suppl 1):1–39.
3. Schneiderman-Walker J, Pollock SL, Corey M, Wilkes DO, Canný GJ, Pedder L, Reissman JJ. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr. 2001;138(3):304–10.
4. Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Physical activity participation by adults with cystic fibrosis: an observational study. Respirology. 2016;21:511–8.
5. Hebestreit H, Huizebos EJH, Schneiderman JE, Karila C, Boas SR, Kriemler S, Dwyer T, Sahllberg M, Unquhart DS, Lands LC, et al. Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis. Am J Respir Crit Care Med. 2019;199(8):887–95.
6. World Health Organization. Global recommendations for physical activity and health. Geneva: WHO Press; 2010.
7. Radtké T, Nevitt SJ, Hebestreit H, Kriemler S. Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev. 2017;Issue(3):CD002768.
8. Dwyer T, Alison JA, McKeeough Z, Davískis E, Bye P. Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis. Chest. 2011;139(4):870–7.
9. White D, Stillier K, Hanselm N. Adherence of adult cystic fibrosis patients with airway clearance and exercise regimens. J Cyst Fibros. 2007;6(3):163–70.
10. Cox NS, Alison JA, Holland AE: Interventions for promoting physical activity in people with cystic fibrosis. Cochrane Database Syst Rev. 2013; (Issue 12).CD009448.
11. Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, Schenk T, Posselt HG, Kriemler S. Long-term effects of a partially supervised conditioning programme in cystic fibrosis. Eur Respir J. 2010;35(3):578–83.
12. Selvdarud HC, Blomkje CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen PM. Randomized controlled study of in-hospital exercise programs in children with cystic fibrosis. Pediatr Pulmonol. 2002;33(3):194–200.
13. Klijn PHC, Oudshoorn A, van der Ent CK, van der Net J, Kimber JP, Pers P. Effects of anaerobic training in children with cystic fibrosis. Chest. 2004;125(4):1290–305.
14. Cox NS, Alison JA, Rasekaba T, Holland AE. Telehealth in cystic fibrosis: a systematic review. J Telemed Telecare. 2012;18(2):72–8.
15. Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Feasibility and acceptability of an internet based program to promote physical activity in adults with cystic fibrosis. Respir Care. 2015;60(3):422–4.
16. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–44.
17. Cox NS, McDonald CF, Alison JA, Mahal A, Woottton R, Hill CJ, Bondarenko J, Macdonald H, Hollowan P, Zanaboni P, et al. Telerehabilitation compared to traditional Centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial. BMC Pulm Med. 2018;18(1):71.
18. Bray SR, Born HA. Transition to university and vigorous physical activity: Implications for health and psychological well-being. J Am Coll Heal. 2004; 52(4):181–8.
19. Schulz KF, Altman DG, Moher D, CONSORT. 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
20. Smyth AR, Bell SC, Bojin S, Bryon M, Duff A, Flume P, Kashkayska N, Munck A, Rajen F, Schwarzenberg SJ, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23–42.
21. Button BM, Wilson C, Dentice R, Cox NS, Middleton A, Tannenbaum E, Bishop J, Cobb R, Burton K, Wood M, et al. Physiotherapy for cystic fibrosis in Australia and New Zealand: a clinical practice guideline. Respirology. 2016;21(4):655–67.
22. Bradley J, O'Neill B, Kent L, Huizebos EJH, Arret B, Hebestreit H. Physical activity assessment in cystic fibrosis: a position statement. J Cyst Fibros. 2015;14(6):e25–32.
23. Trost S, McVet K, Pate RR. Conducting accelerometer-based activity assessments in field-based research. Med Sci Sports Exerc. 2005;37(11):S531–9.
24. Evenson KR, Catellier DJ, Gill K, Onakpala KS, McMurray RG. Calibration of two objective measures of physical activity for children. J Sports Sci. 2008;26(14):1557–65.
25. Troiano RP, Berrigan D, Dodd KW, Masie LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40(1):181–8.
27. Wells G, Wilkes DD, Schneiderman-Walker J, Elmi M, Tullis E, Lands L, Ratjen F, Coates AL. Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis. Pedatr Pulmonol. 2008;43:345–53.

28. Elkins M, Dentice R, Bye PT. Validation of the MST-25: an extension of the modified shuttle test (MST) [Abstract]. J Cyst Fibros. 2009;8(Supplement 2):S70.

29. Bradley J, Howard J, Wallace E, Elborn S. Validity of a modified shuttle test in adult cystic fibrosis. Thorax. 1999;54(3):437–9.

30. Bradley J, Howard J, Wallace E, Elborn S. Reliability, repeatability, and sensitivity of the modified shuttle test in adult cystic fibrosis. Chest. 2000;117(9):1666–71.

31. Rogers D, Smith P, John N, Oliver W, Doull I. Validity of a modified shuttle walk test as a measure of exercise tolerance in paediatric CF patients [abstract]. J Cyst Fibros. 2002;1(Suppl):22.

32. Markland D, Tobin V. A modification to the Behavioural regulation in exercise questionnaire to include an assessment of Amotivation. J Sport Ex Psych. 2004;26(2):191–6.

33. Verloigne M, De Bourdeaudhuij I, Tanghe A, D’Hondt E, Theuwis L, Vansteenkiste M, Deforche B. Self-determined motivation towards physical activity in adolescents treated for obesity: an observational study. Int J Behav Nutr Phys Act. 2011;8(1):97.

34. Vancampfort D, De Hert M, Vansteenkiste M, De Herdt A, Scheewe TW, Soundy A, Stubbs B, Probst M. The importance of self-determined motivation towards physical activity in patients with schizophrenia. Psychiatry Res. 2013;210(3):812–8.

35. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.

36. Quittner AL, Buu A, Messer MA, Modl AC, Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347–54.

37. Zigmond AS, Snith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

38. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.

39. Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Solé A, Tibosch MM, Bergsten Brucefers A, Yüksel H, Catastini P, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the international depression epidemiological study across nine countries. Thorax. 2014;69(12):1090–7.

40. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.

41. Fauroux B, Pepin JL, Boelle PY, Cracovski C, Muris-Espin M, Nove-Josserand R, Stemmler N, Simon T, Burgel PR. Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Arch Dis Child. 2012;97(11):960–6.

42. Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44(10):989–96.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.